Loading…
Vaccine subsidiary of Hualan Biological Engineering, making influenza and other vaccines for the domestic market.
Vaccine subsidiary of Hualan Biological Engineering, making influenza and other vaccines for the domestic market.
Influenza shots in China are mostly category-two vaccines, paid for by individuals rather than the state programme, so sales depend on seasonal uptake and on provincial disease-control centers' procurement. The season is brief, so sales concentrate in the autumn. Its parent, Hualan Biological Engineering, lists separately.
Moat: narrow (regulatory licence, distribution). Leverages parent Hualan's plasma/vaccine manufacturing scale and distribution network.
Headquarters: Xinxiang, China · Employees: 708
Size Hualan Biological Vaccine (301207.SZ) is a China Health Care company (Biotechnology) with a market value of $1.39B, the 1750th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.42 on 6 Nov 2026.
Performance Over six months the shares fell 20.9%, against -20.1% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 19 in its peer set.
Growth Revenue fell 28.4% over the last twelve months (peer median +16.6%); the operating margin is -7.4% (peer median -40.7%).
Valuation It trades at 42.8× forward earnings against a peer median of 27.0× (3rd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +50 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.7 points below its cost of capital (10.0% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥697M | CN¥1.20B | CN¥1.12B | CN¥2.40B | CN¥1.82B |
| Revenue growth | — | +7% | -53% | +32% | — |
| Gross profit | CN¥529M | CN¥894M | CN¥868M | CN¥2.07B | CN¥1.55B |
| EBITDA | n/a | CN¥232M | CN¥237M | CN¥1.03B | CN¥646M |
| Net income | CN¥46.2M | CN¥183M | CN¥206M | CN¥860M | CN¥520M |
| Free cash flow | CN¥486M | CN¥491M | CN¥502M | CN¥878M | CN¥244M |
| Capital expenditure | CN¥20.5M | CN¥9.70M | CN¥51.6M | CN¥62.6M | CN¥92.6M |
| Total debt | CN¥19.6M | CN¥8.49M | CN¥300M | CN¥300M | CN¥315M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hualan Biological Vaccine 301207.SZ | $1.39B | -21% | -28% | -7% | 42.8× | 36.5% |
| Chongqing Zhifei Biological Products 300122.SZ | $5.35B | -2% | -28% | -210% | n/a | -6.4% |
| Walvax Biotechnology 300142.SZ | $2.71B | -12% | -23% | 5% | 381.7× | 31.3% |
| Shenzhen Kangtai Biological Products 300601.SZ | $2.11B | -9% | -9% | 6% | 119.7× | 25.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301207.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.0% | -2.0% | 3rd lowest of 21 |
| 6-month return | -20.9% | -20.1% | 10th highest of 19 |
| Distance from 52-week high | -44.7% | -40.7% | 9th lowest of 21 |
| Revenue growth (TTM) | -28.4% | +16.6% | 3rd lowest of 16 |
| Operating margin | -7.4% | -40.7% | 8th highest of 15 |
| Forward P/E | 42.8× | 27.0× | 3rd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 36.5% | -1.2% | most demanding of 6 |
| Growth delivered (Del g) | -13.1% | +15.0% | lowest of 6 |
| Hurdle (Req g minus delivered) | +49.6 pp | -23.0 pp | most demanding of 6 |
| ROIC minus cost of capital | -8.7 pp | -1.6 pp | 4th lowest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 42.8× | 36.5% | -13.1% |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 8.6× | -1.2% | +25.6% |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 29.4× | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | n/a | n/a | n/a |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | n/a | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | n/a | n/a | n/a |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | n/a | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 46.2× | 8.8% | -7.0% |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 15.7× | -7.9% | +15.0% |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | 48.2× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 7.6× | -4.1% | +33.5% |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 27.0× | 15.8% | +9.9% |